DNLI News and Press, Denali Therapeutics Inc. From 02/07/24

New data show additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm Phase 1/2 study; sustained normalization of CSF heparan sulfate and robust, sustained reduction in neurofilament light chain (...

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal st...

Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readiness Advance broad clinical-stage portfolio of seven therapeutic product candidates across neurodegeneration (ALS, Parkinson’s disease, MS, FTD-GRN), lysosomal storage disease (MP...

2024-01-07 11:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-02 13:57:42 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity’s future. Many misconceive anti-aging stocks as peddling some magic pill that ine...

2023-12-13 15:23:21 ET More on Denali Therapeutics Diving Into Denali Therapeutics Denali's New Summit: Changing Hunter Syndrome Landscape JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower Seeking Alpha’s Quant Rating on Denali ...

2023-12-12 16:51:29 ET Gainers: Innovative International Acquis ( IOAC ) +24% . EF Hutton Acquisition Corporation  ( EFHT ) +5% . Denali Therapeutics  ( DNLI ) +4% . SLM Corporation ( SLM ) +4% . BioCryst Pharmaceuticals ( BC...

2023-12-12 03:49:29 ET Summary Today, we take a deeper look at Denali Therapeutics, a biotech company focused on developing treatments for neurodegenerative and lysosomal storage diseases. Denali's developmental focus has drawn several collaboration partnerships from much larger d...

2023-12-03 00:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...